期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 130, 期 11, 页码 5875-5892出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI134132
关键词
-
资金
- Cancer Research UK (CRUK) [C34648/A18339, C34648/A28278]
- Children with Cancer UK [2014/174, 2016/233]
- Christophers Smile [CSM001X]
- INSTINCT
- SPARKS [12RMH01]
- Neuroblastoma Society
- EU [EU-116064-1]
- ICR
- CRUK
- EPSRC Cancer Imaging Centre [C1060/A10334]
- ICR CRUK Imaging Centre [C1090/A16464]
- Wellcome Trust [091763Z/10/Z]
- NIH
- NCI [1R01CA215452-01]
- German Federal Ministry of Education and Research (BMBF) as part of the SYSMED-NB consortium
- CRUK [C309/A11566, C24461/A23302]
- ICR London
- Cyclacel Ltd.
- MRC
- Department of Health (England)
- MRC [MC_PC_18051, MC_PC_16047] Funding Source: UKRI
The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYCN-amplified neuroblastoma via multiple mechanisms. COK9 - a component of the transcription elongation complex P-TEFb - bound to the MYCN-amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCN-amplified neuroblastoma, MYCN invaded active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed by CYC065. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYC065. CYC065, used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in the treatment of MYCN-amplified neuroblastoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据